Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...
AstraZeneca has begun a new agreement with Daiichi Sankyo to develop and market an antibody to treat cancer, worth up to $6 billion. The deal covers DS-1062, Daiichi Sankyo’s proprietary antibody-drug ...
@yanghoonkim unfortunately today you can not re-use deleted run ids in a project. We provide a helper method wandb.util.generate_id() which can be used to generate a random set of characters to append ...
We read every piece of feedback, and take your input very seriously.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback